Every intervention Outliyr has scored for blood sugar control, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for blood sugar control; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
66 of 117 evaluated interventions score 3.0+ out of 10 for blood sugar control · 17 comparisons
Buse 2025 found higher HbA1c target achievement than alternative treatment in type 2 diabetes. This is the cleanest use case: GLP-1 receptor signaling increases glucose-dependent insulin release, slows gastric emptying, lowers glucagon,…
Tirzepatide improves blood-sugar control, achieving average HbA1c reductions of about 1.5 % in phase 3 trials of type 2 diabetes patients Frias 2021. Tirzepatide's dual GIP and GLP-1 receptor agonism drives stronger…
Metformin also slowed progression from prediabetes to full diabetes in the Diabetes Prevention Program, cutting incidence by roughly 31% compared with placebo Knowler et al. 2002. Both trials are large randomized controlled…
Yin 2008 showed berberine improved glycemic markers in type 2 diabetes, and Lan 2015 supports glucose-lowering direction across randomized trials. This is the most defensible use case, but it remains non-guideline supplement…
Sanyal 2024 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: this verified source reported HbA1c reductions up to -2.02% in type 2 diabetes, with additional 2026…
Asbaghi 2022 anchors the most relevant signal. Magnesium fits blood sugar when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because effects…
Lang 2024 anchors the strongest signal. The existing rationale points to this narrower claim: Zone 2 improves glucose disposal through muscle contraction, GLUT4 activity, and higher weekly energy flux. this verified source…
Tzang 2024 reports 25 RCTs and 1024 participants; lower SBP, DBP, fasting blood glucose, and triglycerides; no significant adverse-effect excess. Systematic 2022 points in the same direction, but route, dose, baseline status,…
The evidence points to a plausible use case without proving a universal response. Dai W et al. 2024 is the best anchor here because it reports 19 randomized trials, 568 participants and…
Polyphenol-rich foods consistently associate with lower type 2 diabetes risk in cohorts, with flavonoids around HR 0.88 and flavan-3-ols near HR 0.89 per pooled prospective data, and a roughly 5 percent risk…
Hatami 2021 pooled 8 studies in type 2 diabetes and found fasting glucose dropping 17.88 mg/dL, although HbA1c did not move significantly. Ghanbari 2022 similarly found a significant fasting-glucose reduction with a…
The evidence points to a plausible use case without proving a universal response. Eshaghhosseiny Z et al. 2024 is the best anchor here because it reports 10 clinical studies and 408 women…
SIT directly improves insulin action. Babraj 2009 cut glucose area-under-curve 12 percent and insulin area-under-curve 37 percent after just six sessions, and Metcalfe 2012 raised insulin sensitivity 28 percent with the minimal…
Kumar 2023 reported HOMA-IR insulin resistance fell 64 percent over 16 weeks in older adults, and the type 2 diabetes pilot Sekhar 2022 found a 22 percent drop in insulin resistance in…
Soh 2024 anchors the most relevant signal. Glycine fits blood sugar because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the endpoint. The score stays bounded because…
Low-load exercise with BFR can increase skeletal-muscle glucose uptake indirectly; evidence is promising but less direct than hypertrophy and rehab data. The score stays bounded because Blood-Flow Restriction Training evidence for blood…
High-intensity interval training can improve glucose regulation in metabolic-syndrome cohorts Poon 2024. The protocol uses repeated near-maximal aerobic efforts that increase muscle glucose uptake and insulin sensitivity after training. Still, Norwegian 4x4…
Effects on fasting insulin and HOMA-IR were inconsistent, and the authors rated overall certainty as low with a call for larger, longer trials. The practical takeaway is that vitamin C is a…
The evidence supports a modest glycemic benefit from Whole-Body Vibration, with a meta-analysis reporting a small but significant reduction in fasting glucose for type 2 diabetes patients (Fabregat-Fernandez 2024). The data suggest…
MOTS-c blood-sugar support comes from AMPK-mediated glucose disposal and mouse insulin-sensitivity findings in Lee 2015. Human data remains biomarker-observational, not dosing-interventional. That makes MOTS-c more defensible when blood sugar is a real…
Blood sugar control is well supported even though the diabetes indication is still pending. In early type 2 diabetes the 36 mg dose lowered HbA1c about 1.48 percent versus 0.41 percent on…
Blood sugar control is a clear strength in the diabetic population. REDEFINE 2 reported that 74% of people with type 2 diabetes reached an HbA1c at or below 6.5%, a target that…
Blood sugar is the most practically tracked sulforaphane endpoint. Axelsson 2017 and Dwibedi 2025 together support a fasting glucose effect in dysregulated subgroups, with Dwibedi 2025 showing a responder subgroup reduction around…
Glucose control is genuinely strong despite the glucagon leg's tendency to raise blood sugar. In the Phase 2 diabetes trial, HbA1c fell about 1.67 percent on 6 mg and 73.5 percent of…
Liu 2024 reports 11 RCTs; 346 healthy participants; significant improvements reported across fatigue, cognition, and exercise-efficiency endpoints overall; endpoint details are limited. Maleki-Hajiagha 2024 points in the same direction, but route, dose,…
The best human anchor is insulin sensitivity, not direct HbA1c or remission data. Kars 2010 found improved hepatic and skeletal-muscle insulin sensitivity after four weeks in obese adults, which is relevant but…
Rodriguez 2016 supports direction more than certainty. The existing rationale points to this narrower claim: Blood-sugar support remains theoretical and community-driven. Methylene blue's redox mechanism may help metabolically stressed users, but no…
A ketone ester acutely lowers blood glucose. Myette-Cote 2018 reported a roughly 17 percent reduction in glucose area-under-curve after an oral glucose tolerance test in 20 healthy adults when ketones were taken…
Lincoff 2023 reports TRAVERSE cardiovascular outcomes trial in 5,246 hypogonadal men with cardiovascular risk; major cardiovascular events non-inferior, with monitoring-relevant safety signals. Cruickshank 2024 points in the same direction, but route, dose,…
SLU-PP-332 aims to boost fatty-acid oxidation, which in rodents reduced fasting glucose and insulin levels, suggesting a mechanistic link to better blood-sugar control. However, the studies remain preclinical; they lack oral pharmacokinetic…
Demidenko 2021 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: No direct human glucose RCTs. Keep near neutral until fasting glucose, insulin, HbA1c, or…
Blood-sugar control is solid but not the headline. In a 16-week type 2 diabetes trial, survodutide up to 2.7 mg per week matched semaglutide 1.0 mg on HbA1c reduction while delivering more…
Human insulin-sensitivity work gives a modest metabolic signal. The strongest support comes from Shimomura Y. et al. 2006, but the practical rating stays bounded by study size, replication, and how directly the…
Pittas 2019 anchors the most relevant signal. Vitamin D3 + K2 fits blood sugar when deficiency, bone risk, immune seasonality, or fat-soluble nutrient gaps are present. The score stays bounded because benefits…
Lamming 2012 anchors the most relevant signal. Rapamycin fits blood sugar when mTORC1 modulation, autophagy, immune aging, or senescence biology is the actual target. The score stays bounded because human longevity endpoints…
The fasting-glucose reduction in Fallah 2018 was small (4.23 mg/dL, P=0.041) and rests on fewer trials than the lipid endpoints, with no strong HbA1c or insulin-sensitivity outcome data behind it. The fiber…
Yoshino 2021 anchors the most relevant signal. NMN fits blood sugar when raising NAD+ is likely to matter for older, metabolically stressed, or performance-tracking users. The score stays bounded because NAD+ rises…
The insulin-sensitivity signal is real but glucose itself rarely moves. In Ham 2024 (75 adults, 12 weeks, 350 mg magnesium) HOMA-IR and fasting insulin both fell, yet fasting glucose and HbA1c were…
Curcumin's glucose-lowering effect is one of its more repeatable metabolic actions. The same 2018 metabolic syndrome meta-analysis found reductions in fasting glucose, HbA1c, and insulin resistance. Effect sizes are small-to-moderate and vary…
Blood sugar control is a direct, mechanistically expected benefit of the dual-incretin design, and the early data backs it. The VENTURE Phase 2 injectable trial saw about 78 percent of prediabetic participants…
Blood-sugar score stays cautious because amino acid metabolites correlate with insulin resistance and future glucose dysregulation in cohorts. This is not proof that EAA supplements cause diabetes.
Blood sugar control is a genuine but secondary benefit. Amylin slows gastric emptying and suppresses glucagon after meals, which blunts glucose spikes, and unlike insulin secretagogues it carries minimal hypoglycemia risk, per…
Blood-sugar support is modest: Zhang 2025 found fasting glucose and HbA1c improvements across cardiometabolic RCTs, but publication-bias and endpoint heterogeneity keep the score mid-range.
Blood-sugar effects are more credible in diabetes or impaired-glucose-tolerance populations than in healthy users. A Cochrane review for adults with type 2 diabetes found very-low-certainty evidence and too little long-term patient-relevant data…
Glycemic data for traditional sauna is thin.
A few meta-analyses report small reductions in fasting glucose or HbA1c in diabetics, but the effect is inconsistent and minor relative to diet, exercise, or medication. CoQ10 is not a glycemic-control tool…
Endothelial protection from hyperglycemia is described mechanistically, but no human glycemic-control trial supports a direct blood-sugar benefit.
Improved glucose tolerance and glycemic control are consistent animal findings (Axelrod et al. 2020), but no human glucose data exists.
Glycemic effects are inconsistent and mostly appear in combination protocols or in already-healthy people, not in isolation for people with poor glucose control. Treat any blood-sugar benefit as unproven for the typical…
HBOT may shift glucose during treatment in patients with diabetes, making monitoring important. McIntosh 2021 reviews intra-session glycemic effects. Evidence does not support using hyperbaric oxygen as primary glycemic control. The practical…
Contracting muscle increases glucose uptake, and more muscle mass can support insulin sensitivity. Direct WB-EMS blood-sugar data remain limited, with Guretzki 2024 showing only a small composite metabolic signal.
Blood-sugar support is modest and indirect. Cortisol reduction can improve insulin sensitivity in stressed users, and v0 evidence included glucose improvements, but ashwagandha is not a diabetes treatment. Users on antidiabetic medications…
No direct glycemic RCT data were identified. Animal and mechanistic signals are not enough for a clinically useful blood-sugar score.
A whole-seaweed RCT showed no glucose benefit and an isolated-fucoidan trial worsened HOMA-IR; human glycemic evidence is unfavorable to neutral.
Tesamorelin can modestly worsen glucose tolerance in susceptible users despite VAT benefits. FDA labeling warns about glucose intolerance and diabetes monitoring, so blood-sugar scoring remains intentionally conservative.
Mixed to null. Klupp 2016 found no HbA1c or fasting-glucose effect from reishi; one small open-label reishi trial and animal chaga data point the other way but are low quality.
The Arabi 2023 umbrella review found no consistent effect on FBG or HOMA-IR, although insulin levels moved in some analyses. Shi 2016 reported no change in glucose despite a 26.5 micromol per…
Any blood-sugar benefit is indirect, riding on the weight loss rather than a measured glycemic endpoint. Losing 9 to 11 percent of body weight reliably improves insulin sensitivity, but no tesofensine trial…
Autonomic balance affects insulin sensitivity; one small study supports.
Magnesium participates in insulin signaling and dehydration can worsen glucose tolerance; electrolyte correction supports baseline physiology without reliably lowering glucose in replete users.
Indirect via PCOS insulin-sensitivity context only. No meaningful direct glycemic-control RCT evidence in the general population.
Animal diabetes data support a weak blood-sugar hypothesis, but peer-reviewed human RCT evidence is absent. Lion's Mane should not be framed as a glucose-control supplement.
Dollerup 2018 was explicitly null for insulin sensitivity in obese men at 2,000 mg/day over 12 weeks, so blood-sugar support remains weak despite NAD+ pathway relevance.
Blood-sugar improvements come mainly from related NNMT inhibitors in mice (Kannt 2018), not direct 5-Amino-1MQ trials.
Robinson 2024 (Robinson 2024) was null on fasting glucose, fasting insulin, and HOMA-IR over 12 weeks at 200 mg/day. Wang 2024 (Wang 2024) adds a preclinical pregnancy caution because maternal pentadecanoic-acid feeding…
Nothing matches those filters.
Monthly out-of-pocket cost at the most accessible legitimate channel, at the dose the score was given for. 20 of 66 are not priced yet; those cells are left blank rather than guessed.
| Intervention | Monthly cost | At dose | How you get it |
|---|---|---|---|
| Semaglutide | $199–$349 | 0.25 mg weeks 1 to 4, 0.5 mg weeks 5 to 8, 1.0 mg weeks 9 to 12, 1.7 mg weeks 13 to 16, 2.4 mg week 17 onward | Prescription |
| Tirzepatide | $299–$449 | 2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg | Prescription |
| Metformin | $4–$30 | 500 mg with dinner for 1 week, then 500 mg twice daily for 1 week, then increase by 500 mg/week toward 1000 mg twice daily as tolerated | Prescription |
| Berberine | $15–$25 | 500 mg berberine HCl three times daily with meals | Over the counter |
| Retatrutide | $130–$960 | 2 mg, then 4 mg, then 8 mg or 12 mg weekly depending on protocol and tolerability | Research use only |
| Magnesium | $10–$20 | 200-400 mg glycinate elemental | Over the counter |
| Zone 2 Cardio | Not priced yet | Over the counter | |
| Taurine | $3–$10 | 1-3 g, 30-60 minutes before sleep | Over the counter |
| Time-Restricted Eating | Not priced yet | ||
| Polyphenols (Dietary) | Not priced yet | ||
| Spirulina | $10–$25 | 1 to 4.5 g/day | Over the counter |
| Ketogenic Diet | $100 | Standard keto, 40-50 g total carbohydrate/day | Over the counter |
| Sprinting (Sprint Interval Training) | Not priced yet | ||
| GlyNAC (Glycine + N-Acetylcysteine) | $10–$30 | Glycine and NAC at ~100 mg/kg/day each | Over the counter |
| Glycine | $2–$3 | 3 g oral glycine | Over the counter |
| Blood-Flow Restriction Training | Not priced yet | ||
| Norwegian 4×4 | Not priced yet | Over the counter | |
| Vitamin C (Ascorbic Acid) | Not priced yet | ||
| Whole-Body Vibration | $50–$100 | 30 Hz, roughly 0.3g, 10-20 min standing | Over the counter |
| MOTS-c | $100–$200 | 5-10 mg SC | Research use only |
| Orforglipron (Foundayo) | $149–$299 | Start low, step up to 36 mg | Prescription |
| CagriSema (Cagrilintide + Semaglutide) | $80–$160 | 0.25 mg, then 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg of each | Research use only |
| Sulforaphane | $25–$60 | Broccoli sprout extract delivering about 150 micromoles sulforaphane per day | Over the counter |
| Mazdutide (IBI362) | $400–$420 | Step up over several weeks to 6 mg | Grey market |
| Astaxanthin | Not priced yet | ||
| TUDCA (Tauroursodeoxycholic Acid) | $12–$91 | 500-1,750 mg | Over the counter |
| Methylene Blue | $13–$40 | 0.5-5 mg oral | Over the counter |
| Exogenous Ketones | $38–$300 | Ester 10 to 25 g BHB | Over the counter |
| TRT (Testosterone Replacement Therapy) | $50–$300 | Clinician-selected formulation at the lowest dose likely to restore physiologic testosterone | Prescription |
| SLU-PP-332 | $30–$80 | 3-5 mg/day oral | Research use only |
| Ca-AKG (Calcium Alpha-Ketoglutarate) | $15–$30 | 1 g/day generic Ca-AKG oral | Over the counter |
| Survodutide (BI 456906) | $300–$500 | 2.4, 4.8, or 6.0 mg | Research use only |
| Grass-Fed Whey Protein | $40–$80 | 20-40 g protein | Over the counter |
| Vitamin D3 + K2 | Not priced yet | ||
| Rapamycin | $15–$50 | 3 mg | Prescription |
| Chlorella | $10–$50 | 5-10 g/day | Over the counter |
| NMN (Nicotinamide Mononucleotide) | $40–$100 | 500 mg/day oral | Over the counter |
| Quinton Marine Plasma (Seawater Minerals) | Not priced yet | ||
| Curcumin | $15–$40 | 500 mg curcuminoids | Over the counter |
| VK2735 (Viking Therapeutics) | $100–$400 | 2.5 to 5 mg | Research use only |
| Essential Amino Acids | Not priced yet | ||
| Cagrilintide (AM833) | $70–$170 | 0.25 mg, then 0.5 mg, 1.0 mg, 1.7 mg, then 2.4 mg | Research use only |
| Saffron | Not priced yet | ||
| Resveratrol | Not priced yet | ||
| Traditional Sauna (Finnish Dry-Heat) | $50 | 15 to 20 minutes at 80 to 100 C | Over the counter |
| Coenzyme Q10 (CoQ10 / Ubiquinol) | $15–$40 | 100-200 mg/day | Over the counter |
| Ergothioneine | Not priced yet | ||
| BAM15 | Not priced yet | ||
| Sodium Butyrate | Not priced yet | ||
| Hyperbaric Oxygen Therapy | $3,000–$6,000 | 2.0 ATA for 90 minutes with air breaks | In clinic |
| Full-Body EMS | Not priced yet | ||
| Ashwagandha | $15–$30 | 300 mg KSM-66 with breakfast and 300 mg with dinner | Over the counter |
| Tongkat Ali | $20–$40 | 200 mg/day Physta standardized extract | Over the counter |
| Fucoidan (Brown Seaweed Polysaccharide) | Not priced yet | ||
| Tesamorelin | $250–$500 | 2 mg subcutaneous daily in the evening | Prescription |
| Adaptogenic Mushrooms (Reishi, Cordyceps, Chaga) | $15–$40 | 1.5 to 1.8 g/day standardized extract | Over the counter |
| Quercetin | $20–$50 | 200 mg/day | Over the counter |
| Tesofensine | Not priced yet | ||
| HRV Biofeedback | $5 | 20 min/session at individual RF (4.5 to 6.5 bpm) | Over the counter |
| Electrolytes | Not priced yet | ||
| NAC (N-Acetylcysteine) | $5–$15 | 600 to 1,200 mg/day | Over the counter |
| Lion’s Mane | $20–$40 | 3 g/day fruiting body extract | Over the counter |
| Glutathione (GSH) | $20–$45 | 1,000 mg/day | Over the counter |
| NR (Nicotinamide Riboside) | $40–$50 | 250-300 mg/day oral | Over the counter |
| 5-Amino-1MQ | $95–$190 | 50 to 100 mg oral, once daily | Grey market |
| C15 (Pentadecanoic Acid) | $40–$50 | 200 mg/day | Over the counter |
Head-to-head reports and category rankings that name a winner on this use case.
This page ranks by the live body-composition subrating, not the overall BioHarmony score, since body composition is the goal this category is built around. Tirzepatide leads both measures.…
This page ranks by the live endurance-cardio subrating, not by BioHarmony overall, and the order flips. SLU-PP-332 leads at 6.5–7.0/10 despite carrying the lowest overall score on the…
No. Berberine scores 6.5–7.0/10 and semaglutide 6.0–6.5/10, and that gap misleads almost everyone who reads it. Berberine scores higher because it is cheap, oral and easy to stop,…
No. Omega-3 scores 6.5–7.0/10 and C15:0 3.0/10, and the evidence behind the two is not close. C15:0 has two small human trials. Omega-3 has outcome trials, prescription forms…
On weight loss they tie, and neither is a drug you can legitimately buy. Both score 7.5/10 for body composition, and both are investigational Lilly molecules with phase…
No, and the reason is mechanical. A drink raises blood ketones in an hour. It does not lower insulin, deplete glycogen or shift fuel use. The diet scores…
Magnesium glycinate is magnesium bound to glycine, so if you take it you already take both. That kills the question for sleep. The real decision: magnesium scores higher…
Sulforaphane scores 6.5–7.0/10 and glutathione 6.0–6.5/10, and both have a delivery problem. Sulforaphane needs active myrosinase or you absorb half as much. Plain oral glutathione barely raises blood…
Different liver problems. NAC scores 8.0–8.5/10 and TUDCA 6.5–7.0/10, and NAC wins liver detox 8.0–8.5/10 against 6.5–7.0/10, but its liver evidence is toxin and oxidative damage. TUDCA owns…
GHRP-2 scores 5.5–6.0/10 and GHRP-6 scores 5.0–5.5/10. Both are ghrelin-receptor peptides doing the same job, and appetite is the only difference that changes a decision. Pick GHRP-2 for…
Metformin scores 6.5–7.0/10 and berberine 6.5–7.0/10, so the gap is meaningless. Metformin owns blood sugar with decades of outcome trials behind it. Berberine owns fatty liver, needs no…
MOTS-c scores 6.5–7.0/10 and SS-31 6.0–6.5/10, and neither one has a human trial behind the use you want. MOTS-c takes blood sugar and body composition. SS-31 takes the…
Semaglutide, at 9.5–10.0 out of 10 for blood sugar control. Buse 2025 found higher HbA1c target achievement than alternative treatment in type 2 diabetes.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 6.0–6.5 out of 10 for blood sugar control.
C15 (Pentadecanoic Acid) scores 3.0–3.5 out of 10 for blood sugar control but only 3.0–3.5 overall, landing in the caution tier once safety, side effects, cost and effort are counted.
66 of the 117 interventions evaluated for blood sugar control score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
